Biology of human cytotoxic CD4 T cells (CD4-CTLs) in viral infections

病毒感染中人类细胞毒性 CD4 T 细胞 (CD4-CTL) 的生物学

• 批准号: 10169569
• 负责人: Pandurangan Vijayanand
• 金额: $ 59.68万
• 依托单位: LA JOLLA INSTITUTE FOR IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-26 至 2021-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10169569
• 关键词: 2019-nCoV; Antigens; B-Lymphocytes; Bacteria; Biology; Bronchoalveolar Lavage; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 vaccine; Cells; Development; Disease; Epitopes; Human; Human Biology; Immune response; Immunologics; Impairment; Infection; Intervention; Knowledge; Lung; Measures; Medical; Patients; Peptides; Peripheral Blood Mononuclear Cell; Phenotype; Resolution; Severity of illness; T cell response; T-Lymphocyte; T-Lymphocyte Epitopes; Techniques; Therapeutic; Vaccines; Virus; Virus Diseases; cost effective; cytokine; cytotoxic; in vivo; innovation; pandemic disease; pathogen; response; therapy development

Overall Component COVID19 is a severe ongoing pandemic. Our understanding of the immune response to this disease is lacking, which impairs both the development of proper therapeutics and a vaccine. Vaccines are one of the most cost effective and extraordinarily successful medical interventions. Most of those vaccines depend on CD4 T+ cells and their help to B cells. We have developed multiple new techniques to study human CD4+ T cells over the past several years, which have have been implementing in our LJI CCHI. The supplement proposed here will facilitate rapid and vigorous pursuit of an understanding of the T cell responses to SARS-CoV2 in humans, which may help in the development of treatments and vaccines for COVID19.

整体组件 COVID19是一种严重的持续大流行。我们对这种疾病的免疫反应缺乏了解， 这既损害了适当疗法的发展，也损害了疫苗的开发。疫苗是成本最高的疫苗之一 有效且非常成功的医疗干预。这些疫苗大多依赖于CD4T+细胞 以及他们对B细胞的帮助。在过去的一段时间里，我们开发了多种新技术来研究人类的CD4+T细胞 几年来，一直在我们的LJI CCHI实施。这里提出的补充建议将有助于 快速和积极地了解人类对SARS-CoV2的T细胞反应，这可能是 帮助开发柯萨奇病毒19的治疗方法和疫苗。